Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

Core Viewpoint - Esperion Therapeutics reported a quarterly loss of $0.10 per share, which was better than the Zacks Consensus Estimate of a loss of $0.14, marking an earnings surprise of 28.57% [1] - The company’s revenue for the quarter was $69.11 million, missing the consensus estimate by 1.28%, but showing significant growth from $32.25 million a year ago [2] Financial Performance - Over the last four quarters, Esperion has surpassed consensus EPS estimates three times [2] - The company has also topped consensus revenue estimates two times during the same period [2] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $63.09 million, and for the current fiscal year, it is -$0.13 on revenues of $310.03 million [7] Stock Performance - Esperion shares have declined approximately 28.2% since the beginning of the year, contrasting with the S&P 500's decline of -0.5% [3] - The stock currently holds a Zacks Rank of 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Esperion's stock performance [5]